{"id":"https://genegraph.clinicalgenome.org/r/c03d1c57-cbca-46a2-ac02-3fb3c921fc27v2.0","type":"EvidenceStrengthAssertion","dc:description":"BARD1 was discovered as a binding partner to BRCA1 in 1996 (Wu et al., PMID: 8944023) and was first reported in relation to hereditary breast cancer in 1998 (Thai et al., PMID: 9425226). BARD1-related cancer predisposition is characterized by a susceptibility to breast cancer with emerging evidence suggesting the association of other cancer types including neuroblastoma. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism(s) or inheritance pattern. Therefore, breast cancer and neuroblastoma have been lumped into this curation. Please note, autosomal dominant familial ovarian cancer (MONDO:0016248) has been curated separately due to conflicting evidence. The mechanism of pathogenicity is loss of function in which BRCA1 binding is disrupted and subsequent loss of DNA damage response. 6 predicted null variants (nonsense and frameshift) and 2 missense variants reported in 8 probands with breast cancer in 5 publications (PMIDs: 2550351, 31371347, 21344236, 23334666, 28726808) are included in this curation. Several case-control studies further support the association of breast cancer (PMIDs: 15342711, 28418444, 28649662, 31036035, 33471991, 35172496). Additionally, a case-control study supports the association of neuroblastoma (PMIDs: 37688579, 37688570, 36747619). More evidence is available in the literature, but the maximum score for genetic evidence (12 Points) has been reached. This gene-disease relationship is also supported by experimental evidence, including in vitro functional assays and animal models (2.5 Points, PMIDs: 18443292, 30925164, 33623049). Cells models with BARD1 variants showed impaired DNA damage in line with the proposed mechanism. In addition, both mammary gland conditional knockout Bard1 mice and a BARD1 variant xenograft model showed development of a breast cancer-like mammary tumor. In summary, there is definitive evidence supporting the relationship between BARD1 and autosomal dominant inherited BARD1-related cancer predisposition. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated as definitive for hereditary breast cancer (MONDO:0016419) by the Breast/Ovarian Cancer GCEP on 08/09/2017. This re-curation as definitive was approved by the ClinGen Hereditary Cancer GCEP on 01/26/2024 (SOP Version 10).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/c03d1c57-cbca-46a2-ac02-3fb3c921fc27","GCISnapshot":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2024-09-03T16:33:05.716Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2024-09-03T17:00:00.000Z","role":"Approver"}],"curationReasons":["ErrorClarification","DiseaseNameUpdate","RecurationTiming"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cebf4cc8-d32d-4a3b-a380-40ada9cdef85","type":"EvidenceLine","dc:description":"Score decreased as no detailed family data. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cebf4cc8-d32d-4a3b-a380-40ada9cdef85_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31371347","allele":{"id":"https://genegraph.clinicalgenome.org/r/55f44554-285a-48d7-ade5-fecab37d5154","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000465.4(BARD1):c.1833dup (p.Asp612Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658796163"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/cebf4cc8-d32d-4a3b-a380-40ada9cdef85_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Impaired apoptosis was identified via RAD51 and gH2ax foci after etoposide treatment. Reduced BARD1 expression in patients with variant.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ec3bf819-48d8-4e1a-8485-faaba4cb5209","type":"EvidenceLine","dc:description":"Score decreased as no detailed family data provided.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec3bf819-48d8-4e1a-8485-faaba4cb5209_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31371347","allele":{"id":"https://genegraph.clinicalgenome.org/r/b063bfc1-7c48-48b3-ad56-a8889d08dfe0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000465.4(BARD1):c.2099del (p.Gly700AlafsTer14)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658796159"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/ec3bf819-48d8-4e1a-8485-faaba4cb5209_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Impaired apoptosis via TUNEL and Annexin V assay. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/265e7605-75e0-4cb6-ac20-5decff43b529","type":"EvidenceLine","dc:description":"Two breast cancer cases in the family. A splicing mutation that skips exon 5.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/265e7605-75e0-4cb6-ac20-5decff43b529_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21344236","allele":{"id":"https://genegraph.clinicalgenome.org/r/be7852aa-c4b0-48f2-b956-e4d2f52c343d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000465.4(BARD1):c.1315-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA350450601"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7664f8a1-636c-4179-b0dd-5294a823abb7","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7664f8a1-636c-4179-b0dd-5294a823abb7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25503501","allele":{"id":"https://genegraph.clinicalgenome.org/r/b31efdfc-1994-417e-ae50-849a1fb8a3fe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000465.4(BARD1):c.1652C>G (p.Ser551Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA333205"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5a1250c1-9113-47c8-87ff-571e44aeebab_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25058500","rdfs:label":"H458","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/5a1250c1-9113-47c8-87ff-571e44aeebab","type":"Family","rdfs:label":"H458","member":{"id":"https://genegraph.clinicalgenome.org/r/326ac4b1-8186-4caa-ad86-7cbb5fbc253d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25058500","rdfs:label":"H458 proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":73,"allele":{"id":"https://genegraph.clinicalgenome.org/r/3436656e-5fa4-4668-b583-97d73f6d1ed9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000465.4(BARD1):c.1811-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA350452409"}},"detectionMethod":"Whole blood samples used for hiseq2000 sequencing. SureSelectXT library prep. Paired end 2x74bp reads. ","firstTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/b8e982dc-ae00-499b-a865-347a089dc6cb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25058500","allele":{"id":"https://genegraph.clinicalgenome.org/r/3436656e-5fa4-4668-b583-97d73f6d1ed9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":"obo:HP_0003003","proband":{"id":"https://genegraph.clinicalgenome.org/r/326ac4b1-8186-4caa-ad86-7cbb5fbc253d"}},{"id":"https://genegraph.clinicalgenome.org/r/13cdd234-4db5-494b-b7f7-47c2b7f1390e_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21344236","rdfs:label":"902","family":{"id":"https://genegraph.clinicalgenome.org/r/13cdd234-4db5-494b-b7f7-47c2b7f1390e","type":"Family","rdfs:label":"902","member":{"id":"https://genegraph.clinicalgenome.org/r/6bb546e5-d6cb-4ef5-a36f-d2b3c07bad80","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21344236","rdfs:label":"902-proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/be7852aa-c4b0-48f2-b956-e4d2f52c343d"},"phenotypes":"obo:HP_0003002","previousTesting":true,"previousTestingDescription":"All of the cases included in the study had previously been screened completely for mutations in\nboth BRCA1 and BRCA2 and were found to be negative.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/265e7605-75e0-4cb6-ac20-5decff43b529_variant_evidence_item"}}},"phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":1,"phenotypes":"obo:HP_0003002","proband":{"id":"https://genegraph.clinicalgenome.org/r/6bb546e5-d6cb-4ef5-a36f-d2b3c07bad80"}},{"id":"https://genegraph.clinicalgenome.org/r/4dd4038c-be4e-4b28-9faf-17fbec511b7c_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21344236","rdfs:label":"1273","family":{"id":"https://genegraph.clinicalgenome.org/r/4dd4038c-be4e-4b28-9faf-17fbec511b7c","type":"Family","rdfs:label":"1273","member":{"id":"https://genegraph.clinicalgenome.org/r/437e2e75-8ad9-43d5-9731-db00ebcaec1a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21344236","rdfs:label":"1273 proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/a45a1750-4a44-4a66-b95c-87997a7aa736","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000465.4(BARD1):c.1690C>T (p.Gln564Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA287518"}},"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/38156e60-e78e-4515-8599-29913e17a730_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21344236","allele":{"id":"https://genegraph.clinicalgenome.org/r/a45a1750-4a44-4a66-b95c-87997a7aa736"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0003002","obo:HP_0003003"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/437e2e75-8ad9-43d5-9731-db00ebcaec1a"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b8e982dc-ae00-499b-a865-347a089dc6cb","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b8e982dc-ae00-499b-a865-347a089dc6cb_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11a3abb9-ca18-4426-8ef1-2515e22574ad","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11a3abb9-ca18-4426-8ef1-2515e22574ad_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35172496","rdfs:label":"Kurian","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/e563712b-b919-4de6-827d-fd8c0584075c","type":"Cohort","allGenotypedSequenced":26384,"alleleFrequency":0.002463614311704063,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11a3abb9-ca18-4426-8ef1-2515e22574ad_cc_evidence_item"}],"numWithVariant":65,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/b0fb65de-db54-413f-a66c-69a7f53514cd","type":"Cohort","allGenotypedSequenced":64649,"alleleFrequency":0.001299324042135222,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11a3abb9-ca18-4426-8ef1-2515e22574ad_cc_evidence_item"}],"numWithVariant":84},"lowerConfidenceLimit":1.35,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.0019,"statisticalSignificanceType":"","statisticalSignificanceValue":2.39,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":4.4}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/99fa4ed4-80db-4479-b239-b3da0c3a3669","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/99fa4ed4-80db-4479-b239-b3da0c3a3669_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28649662","rdfs:label":"slavin","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/28292ff7-4a46-45d6-b6fb-fd982c5e4783","type":"Cohort","allGenotypedSequenced":2134,"alleleFrequency":0.003280224929709466,"detectionMethod":"26 known or proposed breast cancer susceptibility genes","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/99fa4ed4-80db-4479-b239-b3da0c3a3669_cc_evidence_item"}],"numWithVariant":7,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/f650df74-cf52-4499-9378-c501f2f42eb3","type":"Cohort","allGenotypedSequenced":26375,"alleleFrequency":0.001251184834123223,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/99fa4ed4-80db-4479-b239-b3da0c3a3669_cc_evidence_item"}],"numWithVariant":33},"lowerConfidenceLimit":1.34,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.0122,"statisticalSignificanceType":"","statisticalSignificanceValue":3.18,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":7.36}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/836d7795-96e0-4cb0-83cf-25a26ef4a093","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/836d7795-96e0-4cb0-83cf-25a26ef4a093_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31036035","rdfs:label":"GC-HBOC","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/f263219a-7f86-4dcb-b042-8612288d40bb","type":"Cohort","allGenotypedSequenced":4469,"alleleFrequency":0.005146565227120161,"detectionMethod":"ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, RAD51D, and TP53 also tested","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/836d7795-96e0-4cb0-83cf-25a26ef4a093_cc_evidence_item"}],"numWithVariant":23,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/c334c696-f2ef-4082-bc14-12abdf29e35c","type":"Cohort","allGenotypedSequenced":37265,"alleleFrequency":0.000966053938011539,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/836d7795-96e0-4cb0-83cf-25a26ef4a093_cc_evidence_item"}],"numWithVariant":36},"lowerConfidenceLimit":3.17,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.000010,"statisticalSignificanceType":"","statisticalSignificanceValue":5.35,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":9.04}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/01c43d5d-1d48-4301-b7a0-f861c290996f","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/01c43d5d-1d48-4301-b7a0-f861c290996f_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15342711","rdfs:label":"karpinnen","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/21b69f18-9c61-4128-886b-c7a8e9da22b1","type":"Cohort","allGenotypedSequenced":126,"alleleFrequency":0.05555555555555555,"detectionMethod":"PCR based purification of exons and exon/intron boundaries of BARD1 only, followed by sequencing ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/01c43d5d-1d48-4301-b7a0-f861c290996f_cc_evidence_item"}],"numWithVariant":7,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/fb53daa0-c2f2-439d-b638-c2d23f4f380a","type":"Cohort","allGenotypedSequenced":1018,"alleleFrequency":0.0137524557956778,"detectionMethod":"Controls were tested for he Cys557Ser variant only","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/01c43d5d-1d48-4301-b7a0-f861c290996f_cc_evidence_item"}],"numWithVariant":14},"lowerConfidenceLimit":107,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.005,"statisticalSignificanceType":"","statisticalSignificanceValue":4.2,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":10.7}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/6facb512-93f6-47a9-b138-51acdd1d1186","type":"EvidenceLine","dc:description":"Enrichment of P-LP variants in CPGs in neuroblastoma vs. gnomAD 2.1: Cases (8/778), Controls (15/15693), OR=10.7535, p-value=0.0000066, 95%CI=3.9361-27.1293.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6facb512-93f6-47a9-b138-51acdd1d1186_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37688579","rdfs:label":"Kim_NB_2024","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/ed002b1a-2d71-49c2-868d-997e21db3e90","type":"Cohort","allGenotypedSequenced":778,"alleleFrequency":0.0102827763496144,"detectionMethod":"Germline DNA from an independent neuroblastoma cohort  was sequenced using Illumina custom capture panels, including a germline panel newly designed\nfor this study (166 genes see Supplementary Table 2).","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6facb512-93f6-47a9-b138-51acdd1d1186_cc_evidence_item"}],"numWithVariant":8,"relatedCondition":{"id":"obo:MONDO_0005072"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/985a1122-d9a6-406e-97d0-9037d81672a2","type":"Cohort","allGenotypedSequenced":6293,"alleleFrequency":0.0003178134435086604,"detectionMethod":"Cancer-free control data were obtained from the Penn Medicine BioBank (PMBB; n=6295) and the Genome Aggregation Database (gnomAD v2.1) without cancer (n=15 708).","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6facb512-93f6-47a9-b138-51acdd1d1186_cc_evidence_item"}],"numWithVariant":2},"lowerConfidenceLimit":6.4352,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":8.0E-7,"statisticalSignificanceType":"","statisticalSignificanceValue":32.3,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":310.3526}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/e4c9f1b5-020f-4ac6-95fd-4dfb1af31f13","type":"EvidenceLine","dc:description":"This is a large case-control study shows a significant association with moderate odds ratio (OR) 2.09 (1.35â€“3.23) of aggregated pathogenic BARD1 variants with overall breast cancer and an increased association in ER negative OR 5.99 (3.51-10.21) and triple negative breast cancer OR 9.29 (4.58-18.85) (4 points).","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4c9f1b5-020f-4ac6-95fd-4dfb1af31f13_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33471991","rdfs:label":"BCAC Dorling","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/e7c386ce-aee4-4ebc-9274-6f04e9408246","type":"Cohort","allGenotypedSequenced":53461,"alleleFrequency":0.001159723910888311,"detectionMethod":"34 genes analysed","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4c9f1b5-020f-4ac6-95fd-4dfb1af31f13_cc_evidence_item"}],"numWithVariant":62,"relatedCondition":{"id":"obo:MONDO_0007254"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/a481d348-f8a6-4ef4-8486-357e721f2811","type":"Cohort","allGenotypedSequenced":60466,"alleleFrequency":0.0005292230344325737,"detectionMethod":"34 genes analysed","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4c9f1b5-020f-4ac6-95fd-4dfb1af31f13_cc_evidence_item"}],"numWithVariant":32},"lowerConfidenceLimit":1.35,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.00098,"statisticalSignificanceType":"","statisticalSignificanceValue":2.09,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":3.23}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/e54cca9a-ded8-4ac7-814f-cd5a08815a50","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e54cca9a-ded8-4ac7-814f-cd5a08815a50_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28418444","rdfs:label":"couch-ambry","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/da254578-c875-4982-93e8-12dec59dd639","type":"Cohort","allGenotypedSequenced":28536,"alleleFrequency":0.001822259601906364,"detectionMethod":"16panl genes were assessed. BRCA1 and BRCA2 variant containing sampels not included in the analysis","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e54cca9a-ded8-4ac7-814f-cd5a08815a50_cc_evidence_item"}],"numWithVariant":52,"relatedCondition":{"id":"obo:MONDO_0007254"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/c8501107-8485-4aef-ac08-b876a10d72be","type":"Cohort","allGenotypedSequenced":26193,"alleleFrequency":0.0005726720879624327,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e54cca9a-ded8-4ac7-814f-cd5a08815a50_cc_evidence_item"}],"numWithVariant":15},"lowerConfidenceLimit":1.31,"method":{"id":"cg:AggregateVariantAnalysis"},"pValue":0.002261,"statisticalSignificanceType":"","statisticalSignificanceValue":2.16,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":3.63}],"specifiedBy":"GeneValidityCaseControlAggregateVariantAnalysisCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/95cd6c4f-c1ae-4573-a1e7-54ec770e766e","type":"EvidenceLine","dc:description":"Score decreased to reflect that the variant is observed in 2 family members not (yet) observed to have colon cancer, and not validated in a family member with colon cancer.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95cd6c4f-c1ae-4573-a1e7-54ec770e766e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28726808","allele":{"id":"https://genegraph.clinicalgenome.org/r/fdca08c5-69ad-4428-90fb-df8dcd1d7944","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000465.4(BARD1):c.632T>A (p.Leu211Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA350456639"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/38156e60-e78e-4515-8599-29913e17a730","type":"EvidenceLine","dc:description":"Score decreased as no detailed family data provided.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/38156e60-e78e-4515-8599-29913e17a730_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ae5d05f-95cd-402b-a46d-535504edc8d1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7414866a-4707-40b6-9c28-9021ed89341f","type":"FunctionalAlteration","dc:description":"Decreased homology-directed repair (HDR) by a number of missense variants and sensitivity to ionizing radiation and cispaltin.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30925164","rdfs:label":"Adomvich HDR"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/09113d8c-ba63-40f1-9c8f-08b67c6c867c_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/56d4a0d3-752b-4b54-bbe1-9b14dc98abf2","type":"EvidenceLine","dc:description":"Changed score to allocate 2 points across 2 non-human model systems, PMID 18443292 also reports a mouse model with LOF BARD1 variant resulting in a breast cancer like phenotype.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07796aed-42c2-49c5-b736-c334b291d035","type":"Finding","dc:description":"MCF7 derived tumor mass within the local mammary gland and were marked by prominent nucleoli with scant cytoplasm and high proliferation. Tumour had cells with genomic instability, ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33623049","rdfs:label":"li ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d854a1c6-fe36-4b13-97fe-70e4158d3fc5","type":"EvidenceLine","dc:description":"Decreasing the score to allocate 2 points across two similar models, both are LOF variants resulting in breast cancer similar to human phenotype.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/438967c0-f289-4f4e-b5e6-29e91c779377","type":"Finding","dc:description":"Conditional deletion of BARD1 in mammary tissue induced mammary carcinoma that are indistinguishable from BRCA1 mice, which have been reported as  resembling basal-like breast tumors of human BRCA1 mutation carriers. Tumours showed features similar to human breast carcinoma, specifically histopathology similar to, TP53 expression similar to and chromosomal instability similar to human breast carcinoma. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18443292","rdfs:label":"BARD1 CKO - mammary","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5}],"evidenceStrength":"Definitive","sequence":8935,"specifiedBy":"GeneValidityCriteria10","strengthScore":14.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/cYuWrJhxLD4","type":"GeneValidityProposition","disease":"obo:MONDO_0700267","gene":"hgnc:952","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_09113d8c-ba63-40f1-9c8f-08b67c6c867c-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}